Moleculin Biotech gets $2.7M from warrant exercises
Moleculin Biotech, Inc. reported that, after filing its quarterly report for the period ended March 31, 2026, investors exercised warrants to purchase 1,361,500 shares of common stock, generating gross proceeds of approximately $2.7 million for the company.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. reported that, after filing its quarterly report for the period ended March 31, 2026, investors exercised warrants to purchase 1,361,500 shares of common stock, generating gross proceeds of approximately $2.7 million for the company. As of June 29, 2026, Moleculin Biotech had 7,065,000 shares of common stock outstanding. The company also made available an updated corporate presentation, furnished as Exhibit 99.1.
Positive
- None.
Negative
- None.
Insights
Warrant exercises bring in $2.7M and modestly change share count.
The company reports warrant exercises for 1,361,500 shares of common stock, resulting in gross proceeds of about $2.7 million. This represents an inflow of cash without issuing new warrant series, since these warrants were already outstanding.
As of June 29, 2026, total common shares outstanding were 7,065,000. The warrant exercises increase the share count but also remove part of the derivative overhang. The filing does not specify how the new capital will be used.
The furnished corporate presentation in Exhibit 99.1 may offer additional business and pipeline context, but it is designated as furnished rather than filed, so it is not automatically incorporated into other securities law filings.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Warrant exercise proceeds: $2.7 million gross
Warrants exercised: 1,361,500 shares
Shares outstanding: 7,065,000 shares
+1 more
4 metrics
Warrant exercise proceeds
$2.7 million gross
From warrant exercises reported after March 31, 2026 Form 10-Q
Warrants exercised
1,361,500 shares
Shares of common stock underlying exercised warrants
Shares outstanding
7,065,000 shares
Common stock outstanding as of June 29, 2026
Form type
Form 8-K
Current report on warrant exercises and corporate presentation
Key Terms
warrants, gross proceeds, shares of common stock outstanding, Emerging growth company
4 terms
warrants financial
"warrants to purchase 1,361,500 shares of Company common stock have been exercised"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
gross proceeds financial
"have been exercised for gross proceeds of approximately $2.7 million"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
Emerging growth company regulatory
"Emerging growth company Securities registered pursuant to Section 12(b) of the Act"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Moleculin Biotech (MBRX) disclose in its latest 8-K?
Moleculin Biotech reported the exercise of warrants for 1,361,500 common shares, generating approximately $2.7 million in gross proceeds. The company also furnished an updated corporate presentation as Exhibit 99.1, available through its website and referenced in the current report.
How much cash did Moleculin Biotech (MBRX) receive from warrant exercises?
The company received gross proceeds of approximately $2.7 million from the exercise of warrants. These exercises converted rights to buy shares into actual common stock, providing additional cash to Moleculin Biotech while increasing its number of shares outstanding.
How many warrants were exercised according to Moleculin Biotech’s 8-K?
Holders exercised warrants to purchase 1,361,500 shares of Moleculin Biotech common stock. These were previously issued warrants that, upon exercise, became outstanding common shares and delivered cash proceeds to the company as disclosed in the filing.
Did Moleculin Biotech (MBRX) include financial statements in this 8-K?
The 8-K focuses on warrant exercises and an updated corporate presentation. It references Item 9.01 for financial statements and exhibits, but the core disclosure highlights proceeds from warrant exercises and the availability of Exhibit 99.1 rather than new detailed financial statements.
What is Exhibit 99.1 in Moleculin Biotech’s June 30, 2026 8-K?
Exhibit 99.1 is a corporate presentation that Moleculin Biotech is using and has posted on its website. The filing specifies this exhibit is being furnished under Item 7.01, meaning it is not automatically treated as filed for Exchange Act purposes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 30, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol (s) | Name of each exchange on which registered |
The |
Item 7.01 | Regulation FD Disclosure |
On June 30, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 8.01 | Other Events |
Subsequent to the filing on May 14, 2026 of the Company's Form 10-Q for the period ended March 31, 2026, warrants to purchase 1,361,500 shares of Company common stock have been exercised for gross proceeds of approximately $2.7 million. As of June 29, 2026, the Company had 7,065,000 shares of common stock outstanding. |
|
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No. | Description |
99.1 | Investor Presentation dated June 2026 |
104 | Cover page Interactive Data File (formatted as Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC. | |||
Date: | June 30, 2026 | ||
By: | /s/ Jonathan P. Foster | ||
Jonathan P. Foster | |||
Exhibit 99.1
